Allie Karas, MA

Allie Karas is the senior vice president of content at MJH Life Sciences. She attended Rider University and earned a degree in journalism before pursing a masters in magazine writing from New York University. Prior to making a switch to health care news in 2018, Allie spent 6 years in New York City working in political journalism. She enjoys spending time with her husband and 3 kids, cooking, working out, and her dog Bo. Follow her on Twitter at @alliewardkaras or email her at [email protected]

Articles by Allie Karas, MA

Avutometinib and Defactinib Show Durable Results in Ovarian Cancer Study

ByKyle Doherty,Allie Karas, MA

April 14th 2026

New phase 2 data confirms the Avmapki Fakzynja Co-pack offers lasting efficacy and stable safety for patients with recurrent KRAS-mutated LGSOC.

FDA Accepts NDA for TLX101-Px Imaging Agent in Glioma

BySpencer Feldman,Allie Karas, MA

April 10th 2026

FDA accepted the NDA for TLX101-Px, a PET imaging agent for glioma, with a Sept. 11, 2026 decision date, aiming to improve assessment of tumor progression.

AI Tool May Predict Response, Resistance in Advanced RCC

ByKristie L. Kahl,Allie Karas, MA

June 10th 2025

A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.

Aspirin Linked to Lower CRC Recurrence in Patients With PI3K Mutations

ByKristie L. Kahl,Allie Karas, MA

January 25th 2025

Aspirin reduced disease recurrence in patients with PI3K-mutated colorectal cancer, underscoring the value of early genomic testing.

FDA Approves First MSC Therapy in Steroid-Refractory GVHD

ByKristie L. Kahl,Allie Karas, MA

December 18th 2024

FDA gives nod of approval to first derived mesenchymal stromal cell therapy for the treatment of pediatric patients with steroid-refractory acute GVHD.